Lixte Biotechnology (LIXT) Competitors $4.29 +0.14 (+3.37%) Closing price 04:00 PM EasternExtended Trading$4.18 -0.12 (-2.68%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. MURA, LTRN, ACRV, MDCX, CALC, PLUR, CGTX, OVID, STTK, and COEPShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Mural Oncology (MURA), Lantern Pharma (LTRN), Acrivon Therapeutics (ACRV), Medicus Pharma (MDCX), CalciMedica (CALC), Pluri (PLUR), Cognition Therapeutics (CGTX), Ovid Therapeutics (OVID), Shattuck Labs (STTK), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Its Competitors Mural Oncology Lantern Pharma Acrivon Therapeutics Medicus Pharma CalciMedica Pluri Cognition Therapeutics Ovid Therapeutics Shattuck Labs Coeptis Therapeutics Lixte Biotechnology (NASDAQ:LIXT) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Does the media prefer LIXT or MURA? In the previous week, Mural Oncology had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for Mural Oncology and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.00 beat Mural Oncology's score of -0.24 indicating that Lixte Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mural Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in LIXT or MURA? 5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 80.2% of Mural Oncology shares are owned by institutional investors. 14.8% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 2.2% of Mural Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, LIXT or MURA? Lixte Biotechnology has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500. Is LIXT or MURA more profitable? Lixte Biotechnology's return on equity of 0.00% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Lixte BiotechnologyN/A N/A -189.35% Mural Oncology N/A -83.39%-70.70% Which has higher earnings and valuation, LIXT or MURA? Lixte Biotechnology is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLixte BiotechnologyN/AN/A-$3.59M-$1.45-2.96Mural OncologyN/AN/A-$128.51M-$7.67-0.32 Do analysts recommend LIXT or MURA? Mural Oncology has a consensus price target of $12.00, indicating a potential upside of 387.80%. Given Mural Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Mural Oncology is more favorable than Lixte Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryMural Oncology beats Lixte Biotechnology on 8 of the 13 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.50M$3.06B$5.67B$9.49BDividend YieldN/A2.44%4.05%4.00%P/E Ratio-2.9620.8627.9419.95Price / SalesN/A246.06396.5882.68Price / CashN/A41.9636.1958.45Price / Book-3.618.308.635.82Net Income-$3.59M-$55.19M$3.24B$258.42M7 Day Performance13.49%5.07%3.22%1.94%1 Month Performance393.67%17.61%10.72%12.02%1 Year Performance79.69%7.03%34.94%20.80% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology0.0841 of 5 stars$4.29+3.4%N/A+77.4%$11.50MN/A-2.964MURAMural Oncology3.2609 of 5 stars$2.500.0%$12.00+380.2%-28.1%$43.17MN/A-0.33119News CoverageLTRNLantern Pharma2.5822 of 5 stars$3.81-4.5%$25.00+555.8%-11.1%$43.03MN/A-2.0720News CoverageHigh Trading VolumeACRVAcrivon Therapeutics3.3688 of 5 stars$1.42+5.2%$17.71+1,147.5%-80.9%$42.33MN/A-0.6358News CoveragePositive NewsMDCXMedicus Pharma2.3831 of 5 stars$3.06-1.6%$23.50+668.0%N/A$42.21MN/A-2.64N/ANews CoverageCALCCalciMedica3.2853 of 5 stars$3.57+18.5%$16.00+348.4%+5.3%$42.06MN/A-2.2430Positive NewsHigh Trading VolumePLURPluri2.9397 of 5 stars$4.96-4.7%$12.00+142.1%-5.3%$40.93M$330K-0.92150CGTXCognition Therapeutics2.3762 of 5 stars$0.70+6.4%$2.83+307.1%-55.3%$40.54MN/A-0.9520OVIDOvid Therapeutics4.5128 of 5 stars$0.64+16.4%$3.13+388.3%-33.3%$39.11M$548K-1.7360High Trading VolumeSTTKShattuck Labs3.4328 of 5 stars$0.79-2.4%$7.50+849.4%-81.7%$38.76M$5.72M-0.55100Upcoming EarningsCOEPCoeptis Therapeutics0.7565 of 5 stars$10.78+0.9%N/A+115.6%$37.53MN/A-1.842 Related Companies and Tools Related Companies MURA Alternatives LTRN Alternatives ACRV Alternatives MDCX Alternatives CALC Alternatives PLUR Alternatives CGTX Alternatives OVID Alternatives STTK Alternatives COEP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
